- Home
- CRNC vs ALT Comparison
CRNC vs ALT Comparison
Compare CRNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNC | ALT |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.7M | 421.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRNC | ALT |
|---|---|---|
| Price | $10.98 | $3.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.25 | ★ $17.67 |
| AVG Volume (30 Days) | 845.7K | ★ 4.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | $41,000.00 |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $5.85 | $2.56 |
| 52 Week High | $13.74 | $7.73 |
Technical Indicators
Market Signals| Indicator | CRNC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 45.45 |
| Support Level | $10.62 | $2.87 |
| Resistance Level | $11.62 | $4.23 |
| Average True Range (ATR) | 0.79 | 0.16 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 91.85 | 65.00 |
Price Performance
Historical ComparisonAbout CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.